Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117338 | 0.88 | MAPT (0.40) | ACLYPGRMAPTALDH1A1KDM4E | |
| SCHEMBL2119688 | 0.82 | PRF1 (0.47) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2118049 | 0.82 | ALDH1A1 (0.40) | ACLYMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL2117835 | 0.81 | MAPT (0.39) | PGRMAPTALDH1A1HSD17B1HSD17B2 | |
| SCHEMBL2119262 | 0.81 | MAPT (0.37) | ACLYPGRMAPTALDH1A1KDM4E | |
| SCHEMBL2119515 | 0.78 | CCR9 (0.40) | ACLYMAPTALDH1A1HSD17B1HSD17B2 | |
| SCHEMBL2120761 | 0.77 | HSD17B1 (0.43) | ACLYPGRMAPTALDH1A1KDM4E | |
| SCHEMBL29498140 | 0.77 | CYP2C9 (0.47) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2119299 | 0.75 | P2RX7 (0.43) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2116620 | 0.75 | TRIM24 (0.46) | MAPTMEN1KMT2APTGES2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | ACLY 1578/4885PGR 1586/4885MAPT 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.